Science4Beauty Raises €1.6M Seed Led by 4growth VC

Science4Beauty, a Warsaw-based biotechnology company developing cosmeceuticals built on a proprietary recombinant conotoxin, has raised a €1.6 million seed round. The round was led by 4growth VC, with participation from Hard2beat. The funding was announced on September 3, 2026.

What Science4Beauty Does

Science4Beauty develops cosmeceuticals based on a proprietary recombinant conotoxin — a peptide inspired by Conus sea-snail venom that relaxes facial muscles. The company's flagship Miorelaxant Magic line is reported to reduce wrinkle depth by up to 48% in company trials and to prolong botulinum toxin results by approximately two months.

The products are sold direct-to-consumer and through aesthetic medicine clinics, with exports to Austria and Germany. Science4Beauty produces its bioactive peptides in an in-house genetic-engineering laboratory and holds patent filings across ten jurisdictions.

Founded in 2020, the company sits at the intersection of biotechnology, peptide engineering, and the aesthetics market — a combination that gives it both a defensible technical foundation and a clear commercial channel through clinics.

The Round at a Glance

Company: Science4Beauty
Round type: Seed
Amount raised: €1,600,000 EUR
Announcement date: September 3, 2026
Lead investor: 4growth VC
Additional investors: Hard2beat

The Technology Behind the Product

The core of Science4Beauty's proposition is a recombinant conotoxin — a peptide derived from the venom of Conus sea snails. In nature, conotoxins act on neuromuscular signaling; the company's proprietary variant is designed to relax facial muscles, which is the mechanism behind its reported effect on wrinkle depth.

Producing these peptides requires genetic engineering rather than extraction, and Science4Beauty has built that capability in-house. In-house production is significant for a company at seed stage: it reduces dependence on external suppliers, supports quality control, and creates a barrier to replication for competitors without similar laboratory infrastructure.

The company's patent filings across ten jurisdictions indicate an intent to protect the underlying peptide technology across multiple major markets, not just its home market in Poland.

Product Line and Clinical Positioning

The Miorelaxant Magic line is positioned around two claims: a reduction in wrinkle depth of up to 48% in company trials, and an extension of botulinum toxin results by roughly two months. The second claim is particularly relevant to the aesthetic medicine channel, where patients receiving botulinum toxin treatments are often looking to extend the interval between sessions.

Selling both direct-to-consumer and through aesthetic medicine clinics gives Science4Beauty two distinct routes to market. The clinic channel provides professional endorsement and access to patients already invested in aesthetic treatments, while the direct-to-consumer channel allows the company to build brand equity and capture margin.

Geographic Footprint

Science4Beauty is headquartered in Warsaw and exports to Austria and Germany. Those export markets are established aesthetic medicine markets in Central Europe, and they provide an early test of whether the company's products can travel beyond Poland. The ten-jurisdiction patent strategy suggests ambitions beyond that initial footprint.

What the Seed Round Signals

A €1.6 million seed round led by 4growth VC, with Hard2beat participating, gives Science4Beauty capital at a stage when it has a defined product line, an in-house production capability, patent filings in multiple jurisdictions, and early export traction. For acquirers and strategics watching the cosmeceutical and peptide-engineering space, the company represents a rare combination: proprietary biotechnology with a consumer-facing brand and a professional clinic channel.

The aesthetics market has seen sustained interest from both pharmaceutical and consumer beauty players, and companies with defensible peptide IP and in-house manufacturing tend to attract attention as they scale.

Summary

Science4Beauty has raised a €1.6 million seed round led by 4growth VC, with Hard2beat also participating. The Warsaw-based company, founded in 2020, develops cosmeceuticals built on a proprietary recombinant conotoxin, sold through its Miorelaxant Magic line direct-to-consumer and via aesthetic medicine clinics, with exports to Austria and Germany. The round was announced on September 3, 2026.